Passage Bio is a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options. The company is based in Philadelphia, PA and has a research, collaboration and license agreement with the University of Pennsylvania (Penn) and its Gene Therapy Program (GTP). The GTP conducts IND-enabling preclinical work and Passage Bio conducts all clinical development, regulatory strategy and commercialization activities under the agreement. The company has a development portfolio of seven product candidates, with the option to license ten more, with lead programs in GM1 gangliosidosis, frontotemporal dementia and Krabbe disease.
Data Provided by Refinitiv. Minimum 15 minutes delayed.